ArticleJournal of nanobiotechnology2026
Mesenchymal stem cell-derived extracellular vesicles attenuate liver transplantation-induced ischemia/reperfusion injury by suppressing hepatocellular complement C5 expression.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND &
aimsHepatic ischemia-reperfusion injury (HIRI) is an unavoidable complication of liver transplantation (LT) that drives allograft dysfunction and mortality. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) show therapeutic promise, yet their actions within the hepatic network remain incompletely defined. We investigated how MSC-EVs protect against LT-induced HIRI, focusing on intercellular communication and complement-mediated inflammation.
methodsSingle-cell RNA sequencing, single-nucleus ATAC-seq, and spatial transcriptomics were performed in rat LT and mouse HIRI livers with or without MSC-EV treatment. Cell migration assays, AAV-mediated overexpression, and PTPN13-knockdown MSC-EVs were used to prove cellular function and mechanisms.
resultsMSC-EVs attenuated HIRI, improving liver function and reducing histologic injury and hepatocyte apoptosis. Single-cell analyses showed selective curtailment of mononuclear phagocyte and neutrophil recruitment to injured liver. Mechanistically, HIRI induced hepatocyte C5 and C5a, which engaged C5aR1 on mononuclear phagocytes and neutrophils to drive chemotaxis. Consistent with this pathway, MSC-EVs delivered PTPN13 to hepatocytes, lowering C5 and promoting ERK1/2 dephosphorylation and enhanced C/EBPα activity. Elevated C/EBPα activity directly suppressed C5 transcription, whereas PTPN13-depleted MSC-EVs showed diminished efficacy.
conclusionsWe present a single-cell multi-omics atlas of MSC-EV therapy across rat LT and mouse HIRI, supported by clinical data. MSC-EVs mitigated HIRI by lowering hepatocyte C5 and reducing mononuclear phagocyte and neutrophil recruitment. MSC-EV delivery of PTPN13 dephosphorylated ERK1/2 and enhanced C/EBPα, repressing hepatocyte C5 and dampening C5a-C5aR1 signaling. These findings position MSC-EVs as a translational nanotherapy to improve graft outcomes after LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.